A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors
- PMID: 27080977
- PMCID: PMC5084892
- DOI: 10.1681/ASN.2015091065
A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors
Abstract
Accurate identification of risk factors for calcific uremic arteriolopathy (CUA) is necessary to develop preventive strategies for this morbid disease. We investigated whether baseline factors recorded at hemodialysis initiation would identify patients at risk for future CUA in a matched case-control study using data from a large dialysis organization. Hemodialysis patients with newly diagnosed CUA (n=1030) between January 1, 2010, and December 31, 2014, were matched by age, sex, and race in a 1:2 ratio to hemodialysis patients without CUA (n=2060). Mean ages for patients and controls were 54 and 55 years, respectively; 67% of participants were women and 49% were white. Median duration between hemodialysis initiation and subsequent CUA development was 925 days (interquartile range, 273-2185 days). In multivariable conditional logistic regression analyses, diabetes mellitus; higher body mass index; higher levels of serum calcium, phosphorous, and parathyroid hormone; and nutritional vitamin D, cinacalcet, and warfarin treatments were associated with increased odds of subsequent CUA development. Compared with patients with diabetes receiving no insulin injections, those receiving insulin injections had a dose-response increase in the odds of CUA involving lower abdomen and/or upper thigh areas (odds ratio, 1.49; 95% confidence interval, 1.03 to 2.51 for one or two injections per day; odds ratio, 1.88; 95% confidence interval, 1.30 to 3.43 for 3 injections per day; odds ratio, 3.74; 95% confidence interval, 2.28 to 6.25 for more than three injections per day), suggesting a dose-effect relationship between recurrent skin trauma and CUA risk. The presence of risk factors months to years before CUA development observed in this study will direct the design of preventive strategies and inform CUA pathobiology.
Keywords: clinical epidemiology; diabetes mellitus; end stage kidney disease; hemodialysis; obesity; vascular calcification.
Copyright © 2016 by the American Society of Nephrology.
Figures


Comment in
-
Calcific Uremic Arteriolopathy Revisited.J Am Soc Nephrol. 2016 Nov;27(11):3233-3235. doi: 10.1681/ASN.2016040480. Epub 2016 May 25. J Am Soc Nephrol. 2016. PMID: 27225039 Free PMC article. No abstract available.
Similar articles
-
The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial.Clin J Am Soc Nephrol. 2015 May 7;10(5):800-7. doi: 10.2215/CJN.10221014. Epub 2015 Apr 17. Clin J Am Soc Nephrol. 2015. PMID: 25887067 Free PMC article. Clinical Trial.
-
Localization, Morphologic Features, and Chemical Composition of Calciphylaxis-Related Skin Deposits in Patients With Calcific Uremic Arteriolopathy.JAMA Dermatol. 2019 Jul 1;155(7):789-796. doi: 10.1001/jamadermatol.2019.0381. JAMA Dermatol. 2019. PMID: 31116362 Free PMC article.
-
Clinical characteristics and risk factors associated with mortality in calcific uremic arteriolopathy.Int Urol Nephrol. 2017 Dec;49(12):2247-2256. doi: 10.1007/s11255-017-1721-9. Epub 2017 Oct 20. Int Urol Nephrol. 2017. PMID: 29058165
-
Multidisciplinary approach to calcific uremic arteriolopathy.Curr Opin Nephrol Hypertens. 2015 Nov;24(6):531-7. doi: 10.1097/MNH.0000000000000175. Curr Opin Nephrol Hypertens. 2015. PMID: 26371529 Review.
-
Calcific uremic arteriolopathy: contemporary pharmacotherapy.Adv Chronic Kidney Dis. 2010 Sep;17(5):428-38. doi: 10.1053/j.ackd.2010.05.006. Adv Chronic Kidney Dis. 2010. PMID: 20727513 Review.
Cited by
-
Development of the BWAT-CUA Scale to Assess Wounds in Patients with Calciphylaxis.Diagnostics (Basel). 2021 Apr 20;11(4):730. doi: 10.3390/diagnostics11040730. Diagnostics (Basel). 2021. PMID: 33924020 Free PMC article.
-
Successful Novel Treatment of Nonuremic Calciphylaxis with Sodium Thiosulfate and Iloprost: A Case Report.Case Rep Dermatol. 2022 Sep 19;14(3):269-274. doi: 10.1159/000525712. eCollection 2022 Sep-Dec. Case Rep Dermatol. 2022. PMID: 36824154 Free PMC article.
-
Chronic skin ulcers in hemodialysis patient: A fatal case of calciphylaxis.Radiol Case Rep. 2023 Feb 7;18(4):1522-1526. doi: 10.1016/j.radcr.2023.01.053. eCollection 2023 Apr. Radiol Case Rep. 2023. PMID: 36824989 Free PMC article.
-
Early diagnosis strategy of calciphylaxis in dialysis patients.Ren Fail. 2023;45(2):2264407. doi: 10.1080/0886022X.2023.2264407. Epub 2023 Oct 5. Ren Fail. 2023. PMID: 37795796 Free PMC article. Review.
-
Calciphylaxis of the Upper Limbs-A Rare and Serious Disease with Multidisciplinary Treatments-A Case Series and Literature Review.Diagnostics (Basel). 2025 May 6;15(9):1179. doi: 10.3390/diagnostics15091179. Diagnostics (Basel). 2025. PMID: 40361997 Free PMC article.
References
-
- Hayden MR, Kolb LG, Khanna R: Calciphylaxis and the cardiometabolic syndrome. J Cardiometab Syndr 1: 76–79, 2006 - PubMed
-
- Angelis M, Wong LL, Myers SA, Wong LM: Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery 122: 1083–1089, discussion 1089–1090, 1997 - PubMed
-
- Hayashi M, Takamatsu I, Kanno Y, Yoshida T, Abe T, Sato Y Japanese Calciphylaxis Study Group : A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant 27: 1580–1584, 2012 - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical